Literature DB >> 10440397

Recurrence of autoimmune hepatitis after liver transplantation.

P Milkiewicz1, S G Hubscher, G Skiba, M Hathaway, E Elias.   

Abstract

BACKGROUND: The literature data on the recurrence of autoimmune hepatitis (AIH) after orthotopic liver transplantation (OLTX) is scanty.
METHODS: We analyzed the frequency of recurrent AIH in 47 patients who had been transplanted for AIH and survived at least 1 year after surgery. The following criteria were applied to diagnose recurrence: (1) positive autoantibodies in the titer> or =1:40; (2) hypertransaminasemia; (3) histological features of chronic hepatitis; (4) need of reintroduction or significant increase of steroids; and (5) lack of serum markers of viral hepatitis.
RESULTS: A total of 13 patients (1 male/12 females) developed recurrent AIH after an interval of 6-63 months after OLTX (mean 29 months). Mean AST level at recurrence was 542+/-129 U/L. Three patients from this group needed regrafting. Mismatch of DR3+ recipient and DR3- donor was not more common in the recurrent disease group (37%) compared to the nonrecurrence group (31%) (P=NS).
CONCLUSIONS: Recurrence of AIH after OLTX was diagnosed in a high proportion of patients and some of them required regrafting. DR3+ patients are not particularly prone to develop recurrence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440397     DOI: 10.1097/00007890-199907270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  27 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.

Authors:  Ayako Suzuki; Elizabeth M Brunt; David E Kleiner; Rosa Miquel; Thomas C Smyrk; Raul J Andrade; M Isabel Lucena; Agustin Castiella; Keith Lindor; Einar Björnsson
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

3.  Role of international criteria in the diagnosis of autoimmune hepatitis.

Authors:  Mohammad Reza Abdollahi; Mohammad Hossein Somi; Esmaeil Faraji
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

Review 4.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients.

Authors:  Nader Dbouk; Samir Parekh
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

Review 6.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

7.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 8.  Autoimmune Hepatitis in the Liver Transplant Graft.

Authors:  Eliza W Beal; Sylvester M Black; Anthony Michaels
Journal:  Clin Liver Dis       Date:  2017-05       Impact factor: 6.126

9.  A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence.

Authors:  J-C Duclos-Vallée; M Sebagh; K Rifai; C Johanet; E Ballot; C Guettier; V Karam; M Hurtova; C Feray; M Reynes; H Bismuth; D Samuel
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 10.  Transplantation in autoimmune liver diseases.

Authors:  Marcus Mottershead; James Neuberger
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.